{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:17:48Z","timestamp":1790705868000,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.lpm.2013.04.002","type":"journal-article","created":{"date-parts":[[2013,5,2]],"date-time":"2013-05-02T12:09:23Z","timestamp":1367496563000},"page":"861-870","source":"Crossref","is-referenced-by-count":5,"title":["Prise en charge du diab\u00e8te de type 2\u00a0: anciens ou nouveaux m\u00e9dicaments, comment choisir\u00a0?"],"prefix":"10.1016","volume":"42","author":[{"given":"Serge","family":"Halimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2013.04.002_bib0005","first-page":"766","article-title":"Analyse du m\u00e9canisme de l\u2019action hypoglyc\u00e9miante du p-amino-benz\u00e8ne-sulfamido-isopromyl-thiodiazol (2254\u00a0RP)","volume":"138","author":"Loubati\u00e8res","year":"1944","journal-title":"CR Soc Biol (Paris)"},{"key":"10.1016\/j.lpm.2013.04.002_bib0010","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S1262-3636(07)70309-9","article-title":"Metformin: 50years old, fit as a fiddle, and indispensable for its pivotal role in type 2\u00a0diabetes management","volume":"32","author":"Halimi","year":"2006","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.lpm.2013.04.002_bib0015","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJMoa0806359","article-title":"Long-term follow-up after tight control of blood pressure in type 2\u00a0diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2013.04.002_bib0020","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2\u00a0diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"issue":"Cahier 2","key":"10.1016\/j.lpm.2013.04.002_bib0025","first-page":"1S1","article-title":"Traitement m\u00e9dicamenteux du diab\u00e8te de type 2 (Actualisation). Recommandations de bonne pratique","volume":"33","year":"2007","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.lpm.2013.04.002_bib0030","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"Nauck","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.lpm.2013.04.002_bib0035","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1006524","article-title":"Long-term effects of intensive glucose lowering on cardiovascular outcomes","volume":"364","author":"Gerstein","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.lpm.2013.04.002_bib0040","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jacc.2008.10.008","volume":"53","author":"Skyler","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2013.04.002_bib0045","doi-asserted-by":"crossref","first-page":"b4909","DOI":"10.1136\/bmj.b4909","article-title":"The association between symptomatic, severe hypoglycaemia and mortality in type 2\u00a0diabetes: retrospective epidemiological analysis of the ACCORD study","volume":"340","author":"Bonds","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.lpm.2013.04.002_bib0050","unstructured":"Cnamts\u00a0\u2013\u00a0DSES\u00a0\u2013\u00a0DESP\u00a0\u2013\u00a0Risque de cancer de la vessie chez les personnes diab\u00e9tiques trait\u00e9es par pioglitazone en France\u00a0: une \u00e9tude de cohorte sur les donn\u00e9es du SNIIRAM et du PMSI\u00a0: 07\/06\/2011. http:\/\/www.afssaps.fr\/Activites\/Surveillance-des-medicaments\/Medicaments."},{"key":"10.1016\/j.lpm.2013.04.002_bib0055","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2\u00a0diabetes mellitus","volume":"58","author":"De Fronzo","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.lpm.2013.04.002_bib0060","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","article-title":"Cardioprotective and vasodilatory actions of glucagon-like peptide 1\u00a0receptor are mediated through both glucagon-like peptide 1\u00a0receptor-dependent and -independent pathways","volume":"117","author":"Ban","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2013.04.002_bib0065","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.diabet.2011.11.001","article-title":"DPP-4\u00a0inhibitors in the management of type 2\u00a0diabetes: a critical review of head-to-head trials","volume":"38","author":"Scheen","year":"2012","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.lpm.2013.04.002_bib0070","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/j.1464-5491.2010.03131.x","article-title":"Linagliptin (BI 1356), a potent and selective DPP-4\u00a0inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2\u00a0diabetes","volume":"27","author":"Forst","year":"2010","journal-title":"Diabet Med"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.lpm.2013.04.002_bib0075","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/S1262-3636(08)73400-1","article-title":"DPP-4\u00a0inhibitors and GLP-1\u00a0analogues: for whom? Which place for incretins in the management of type 2\u00a0diabetic patients?","volume":"34","author":"Halimi","year":"2008","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.lpm.2013.04.002_bib0080","doi-asserted-by":"crossref","DOI":"10.1517\/17425255.2013.777428","article-title":"Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease","author":"Scheen","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.lpm.2013.04.002_bib0085","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1463-1326.2006.00704.x","article-title":"Efficacy and safety of the dipeptidyl peptidase-4\u00a0inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2\u00a0diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial","volume":"9","author":"Nauck","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.lpm.2013.04.002_bib0090","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1463-1326.2010.01233.x","article-title":"Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study","volume":"12","author":"Matthews","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.lpm.2013.04.002_bib0095","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1463-1326.2009.01040.x","article-title":"Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2\u00a0diabetes mellitus","volume":"11","author":"Bosi","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.lpm.2013.04.002_bib0100","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.2337\/dc06-0706","article-title":"Efficacy and safety of the dipeptidyl peptidase-4\u00a0inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2\u00a0diabetes inadequately controlled with metformin alone","volume":"29","author":"Charbonnel","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lpm.2013.04.002_bib0105","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-6823-10-7","article-title":"Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246\u00a0patients with type 2\u00a0diabetes","volume":"10","author":"Williams-Herman","year":"2010","journal-title":"BMC Endo Dis"},{"key":"10.1016\/j.lpm.2013.04.002_bib0110","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jama.2010.405","article-title":"Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2\u00a0diabetes","volume":"303","author":"Phung","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.lpm.2013.04.002_bib0115","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of Exenatide (Exendin-4) on glycemic control over 30\u00a0weeks in patients with type 2\u00a0diabetes treated with metformin and a sulfonylurea","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lpm.2013.04.002_bib0120","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","article-title":"Liraglutide vs. insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2\u00a0diabetes mellitus (LEAD-5\u00a0met+SU): a randomised controlled trial","volume":"52","author":"Russell-Jones","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.lpm.2013.04.002_bib0125","doi-asserted-by":"crossref","DOI":"10.2337\/dc12-2006","article-title":"Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2\u00a0diabetes inadequately controlled on metformin (GetGoal-M)","author":"Ahr\u00e9n","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lpm.2013.04.002_bib0130","first-page":"503","article-title":"Lixisenatide, a novel GLP-1\u00a0receptor agonist for the treatment of type 2\u00a0diabetes mellitus","volume":"12","author":"Christensen","year":"2009","journal-title":"IDrugs"},{"key":"10.1016\/j.lpm.2013.04.002_bib0135","doi-asserted-by":"crossref","first-page":"672658","DOI":"10.1155\/2012\/672658","article-title":"Effects of glucagon-like peptide 1\u00a0receptor agonists on body weight: a meta-analysis","volume":"2012","author":"Monami","year":"2012","journal-title":"Exp Diabetes Res"},{"key":"10.1016\/j.lpm.2013.04.002_bib0145","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1210\/jc.2011-0599","article-title":"The safety of incretin-based therapies: review of the scientific evidence","volume":"96","author":"Drucker","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2013.04.002_bib0150","doi-asserted-by":"crossref","first-page":"602","DOI":"10.7326\/0003-4819-154-9-201105030-00336","article-title":"Comparative effectiveness and safety of medications for type 2\u00a0diabetes: an update including new drugs and drug combinations","volume":"154","author":"Bennett","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2013.04.002_bib0155","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1464-5491.2010.02973.x","article-title":"Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report","volume":"27","author":"Skalli","year":"2010","journal-title":"Diabet Med"},{"key":"10.1016\/j.lpm.2013.04.002_bib0160","doi-asserted-by":"crossref","DOI":"10.2337\/db12-1686","article-title":"Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors","author":"Butler","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.lpm.2013.04.002_bib0165","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-012-2534-0","article-title":"Management of hyperglycaemia in type 2\u00a0diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"55","author":"Inzucchi","year":"2012","journal-title":"Diabetologia"},{"issue":"36","key":"10.1016\/j.lpm.2013.04.002_bib0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta14360","article-title":"Newer agents for blood glucose control in type 2\u00a0diabetes: systematic review and economic evaluation","volume":"14","author":"Waugh","year":"2010","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.lpm.2013.04.002_bib0175","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMsa1103053","article-title":"Emergency hospitalizations for adverse drug events in older Americans","volume":"365","author":"Budnitz","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2013.04.002_bib0180","doi-asserted-by":"crossref","first-page":"A2","DOI":"10.1016\/S1262-3636(13)71621-5","article-title":"Fr\u00e9quence, typologie des patients et co\u00fbt m\u00e9dico-\u00e9conomique des hypoglyc\u00e9mies iatrog\u00e8nes s\u00e9v\u00e8res chez des diab\u00e9tiques de type 2\u00a0sur un territoire de sant\u00e9 en France","volume":"39","author":"Halimi1","year":"2013","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.lpm.2013.04.002_bib0185","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0168-8227(00)00163-7","article-title":"Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with type 2\u00a0diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study","volume":"50","author":"Halimi","year":"2000","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.lpm.2013.04.002_bib0190","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1185\/03007995.2010.485881","article-title":"Role of vildagliptin in managing type 2\u00a0diabetes mellitus in the elderly","volume":"26","author":"Halimi","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.lpm.2013.04.002_bib0195","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2174\/138920011794520053","article-title":"Antidiabetic agents in patients with chronic kidney disease and endstage renal disease on dialysis: metabolism and clinical practice","volume":"12","author":"Abe","year":"2011","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.lpm.2013.04.002_bib0200","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000295848","article-title":"Islamic fasting and health","volume":"56","author":"Azzizi","year":"2010","journal-title":"Ann Nutr Metab"},{"key":"10.1016\/j.lpm.2013.04.002_bib0205","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1185\/03007995.2011.579951","article-title":"Comparison of the dipeptidyl peptidase-4\u00a0inhibitor vildagliptin andthe sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2\u00a0diabetes mellitus fasting during Ramadan: results of the VECTOR study","volume":"27","author":"Barnett","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.lpm.2013.04.002_bib0210","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1185\/03007995.2012.707119","article-title":"Hypoglycemia in patients with type 2\u00a0diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study","volume":"28","author":"Aravind","year":"2012","journal-title":"Curr Med Res Opin"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.lpm.2013.04.002_bib0215","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1463-1326.2008.00883.x","article-title":"Hypoglycaemia in patients with type 2\u00a0diabetes treated with a combination of metformin and sulphonylurea therapy in France","volume":"10","author":"Vexiau","year":"2008","journal-title":"Diabetes Obes Metab"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498213005423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498213005423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T04:23:02Z","timestamp":1539663782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498213005423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0755498213005423"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2013.04.002","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}